Showing 21-30 of 135 results for "".
Journal Club: Comparing Recommendations from Different AD Guidelines
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-comparing-recommendations-from-different-ad-guidelines/24466/Peter Lio, MD, talks with Robert Sidbury, MD, MPH, a pediatric dermatologist at Seattle Children's Hospital, about some of the differences in recommendations from the Annals of Allergy, Asthma, and Immunology Joint Task Force AD guidelines, and the Journal of the American Academy of Dermatology (JAADermWireTV: Skyrizi for PsA; Toxins and Wound Healing at Maui Derm; SDDS Registration
https://practicaldermatology.com/topics/psoriasis/skyrizi-for-psa-toxins-and-wound-healing-at-maui-derm-sdds-registration-dermwiretv/20057/Skyrizi (AbbVie) is now approved for the treatment of adults with active psoriatic arthritis. Michael Gold, MD was among the speakers who offered updates on cosmetic trends as well as medical care at Maui Dermatology for Dermatologists last week. He spoke about high-dose neurotoxins. Robert KirsnerNew in My Practice: OTC
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-otc-3/23492/Hair’s the Thing
https://practicaldermatology.com/topics/hair-nails/hairs-the-thing/23909/Dermatologists can take a more proactive role in caring for patients with alopecia.Currents: Think Big
https://practicaldermatology.com/topics/skin-cancer-photoprotection/currents-think-big/20893/Big picture approaches can unlock new solutions to dermatologic diseases.New In My Practice: Rx
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-rx/23242/Editorial Board Forum, Part II: What the Future Holds for Dermatology
https://practicaldermatology.com/topics/practice-management/editorial-board-forum-part-ii-what-the-future-holds-for-dermatology/21447/Lichen Amyloidosis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/lichen-amyloidosis/20681/Melanoma Treatment Landscape Evolves
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-treatment-landscape-evolves/21314/The first agent to target the PD-1 pathway, pembrolizumab may prolong life expectancy in some patients.Be Flexible in Your Financial Planning
https://practicaldermatology.com/topics/practice-management/be-flexible-in-your-financial-planning/22070/